1044243-49-3Relevant academic research and scientific papers
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY
-
Paragraph 0346-0347, (2020/07/07)
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 50 skipping are described. In various aspects, antisense oligomers are described according to Formula (I): or a pharmaceutically acceptable salt thereo
EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
-
Page/Page column 133-134, (2020/01/08)
Antisense oligomers and antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS
-
, (2019/04/16)
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
-
Paragraph 0309; 0310, (2018/07/15)
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
-
Page/Page column 86; 87, (2018/07/29)
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
-
Page/Page column 86-88, (2018/07/22)
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
PROCESSES FOR PREPARING OLIGOMERS
-
, (2017/12/29)
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS
-
Page/Page column 37, (2016/12/22)
Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.
